Pure Global: Brazil's New SaMD Hurdle & ANVISA's Unspoken Rules.

This week on LATAM MedTech Insights, we dissect the immediate impact of a surprise guidance note issued by Brazil's ANVISA. This new clarification on regulation RDC 751 is tightening the screws on foreign medical device manufacturers, especially those in the digital health and SaMD space. We explore the heightened requirements for technical dossiers and clinical data that are catching companies off guard. Discover why your existing FDA or CE mark documentation may no longer be enough for the Brazilian market. We use the real-world example of an AI diagnostic company suddenly facing major delays and costs, highlighting the critical need for a proactive and localized regulatory strategy to avoid common pitfalls. Key questions from this episode: - What specific change in ANVISA’s enforcement of RDC 751 caught the industry by surprise last week? - Why is foreign clinical data now facing greater scrutiny for SaMD submissions in Brazil? - How has the role of the Brazil Registration Holder (BRH) shifted from a legal formality to a critical strategic partner? - What are the three biggest mistakes manufacturers make when preparing their technical dossier for ANVISA? - Is Brazil's regulatory landscape becoming a barrier or an opportunity for high-quality MedTech? - Could your device's cybersecurity protocols be the hidden factor that leads to rejection? - How do you demonstrate clinical applicability to Brazil's diverse population without running entirely new trials? Navigating complex regulatory shifts like this is what we do best. Pure Global offers end-to-end solutions for MedTech companies, combining local experts in Brazil with advanced AI tools to streamline your path to market. From regulatory strategy and local representation to compiling your technical dossier, we ensure you're prepared for ANVISA's toughest questions. Don't let regulatory hurdles block your entry into Latin America's top market. Contact us at [email protected] or visit https://pureglobal.com/ to learn more.